Welcome to the unCommon Era (0 uCE).
Using the latest technologies to efficiently build drugs that target the underlying cause of rare uncommon diseases
First indication: Rett Syndrome
Neurodevelopmental monogenetic disease that impacts 1 in 10,000 girls
Our uncommon approach
Deep domain and motivated disease experts that truly understand its impact on patients.
Utilizing a multi-modal approach, appreciating the strengths and weaknesses of each modality.
Each drug should stand on its own, but in combination could deliver a cure.
Our deep disease expertise and uncommon approach has unlocked multiple therapeutics that will improve patient lives and in combination could deliver a cure.